Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CymaBay Therapeutics, Inc.CBAY · Entity 92768 | Chief Medical Officer | April 13, 2023 | April 17, 2023 |
| Larimar Therapeutics, Inc.ZFGN · Entity 5634 | Chief Medical Officer | January 22, 2019 | January 24, 2019 |
| Skye Bioscience, Inc.EMBI · Entity 8098 | Chief Medical Officer | August 07, 2020 | August 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CymaBay Therapeutics, Inc.
Report date April 13, 2023 · Filed April 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,000 |
Ending reported balance
After 2023-04-17 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-04-13 · Exercise / conversion · Acquired 7,781 · Balance 27,781 Row 2 · 2023-04-13 · Sale · Disposed 7,781 · Balance 20,000 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $8.985, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2023-04-17 · Exercise / conversion · Acquired 112,219 · Balance 132,219 Row 4 · 2023-04-17 · Sale · Disposed 112,219 · Balance 20,000 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.80, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.37 · Expires 2031-05-16 | Direct | 282,119 |
Reported balance
After 2023-04-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-04-13 · Exercise / conversion · Disposed 7,781 · Balance 282,119 F3: The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.37 · Expires 2031-05-16 | Direct | 169,900 |
Reported balance
After 2023-04-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-04-17 · Exercise / conversion · Disposed 112,219 · Balance 169,900 F3: The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $8.985, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.80, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter.
Larimar Therapeutics, Inc.
Report date January 22, 2019 · Filed January 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 · Expires 2029-01-22 | Direct | 95,000 |
Reported balance
After 2019-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-22 · Grant · Acquired 95,000 · Balance 95,000 F1: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months.
Skye Bioscience, Inc.
Report date August 07, 2020 · Filed August 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2030-08-07 | Direct | 4,736,541 |
Reported balance
After 2020-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-07 · Grant · Acquired 4,000,000 · Balance 4,736,541 F1: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four years. |
Filing footnotes · ownership attribution and instrument terms
F1: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2023 Filed Apr 17, 2023 19:24 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 112,219 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001062993-23-009245 · form4.xml · derivative · entry 6 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,900 Underlying: Common Stock · 112,219 shares Expires 2031-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| April 17, 2023 Filed Apr 17, 2023 19:24 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 112,219 | $9.54 | $1,070,535.59 |
DisclosureSEC source: 0001062993-23-009245 · form4.xml · nonDerivative · entry 4 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.80, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 17, 2023 Filed Apr 17, 2023 19:24 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 112,219 | $4.37 | $490,397.03 |
DisclosureSEC source: 0001062993-23-009245 · form4.xml · nonDerivative · entry 3 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 19:24 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,781 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001062993-23-009245 · form4.xml · derivative · entry 5 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,119 Underlying: Common Stock · 7,781 shares Expires 2031-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 19:24 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 7,781 | $8.98 | $69,880.38 |
DisclosureSEC source: 0001062993-23-009245 · form4.xml · nonDerivative · entry 2 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.98 to $8.985, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 13, 2023 Filed Apr 17, 2023 19:24 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 7,781 | $4.37 | $34,002.97 |
DisclosureSEC source: 0001062993-23-009245 · form4.xml · nonDerivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 17:39 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001062993-23-008102 · form4.xml · derivative · entry 3 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,900 Underlying: Common Stock · 100 shares Expires 2031-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The original option grant vested as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 17:39 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | SaleCommon Stock | 100 | $8.99 | $898.50 |
DisclosureSEC source: 0001062993-23-008102 · form4.xml · nonDerivative · entry 2 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 17:39 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | Exercise / conversionCommon Stock | 100 | $4.37 | $437.00 |
DisclosureSEC source: 0001062993-23-008102 · form4.xml · nonDerivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 16:30 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001062993-23-001494 · form4.xml · derivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2033-01-24 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2023. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 16:56 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 133,333 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001062993-22-001699 · form4.xml · derivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,333 Underlying: Common Stock · 133,333 shares Expires 2032-01-24 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2022. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 16:35 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | PurchaseCommon Stock | 20,000 | $3.04 | $60,800.00 |
DisclosureSEC source: 0001062993-22-001295 · form4.xml · nonDerivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| May 17, 2021 Filed May 17, 2021 18:57 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001062993-21-004767 · form4.xml · derivative · entry 2 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-16 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| May 17, 2021 Filed May 17, 2021 18:57 UTC | CymaBay Therapeutics, Inc. CBAY · Entity 92768 | GrantEmployee Stock Option (right to buy) · Derivative | 390,000 | $0.00 Strike: $4.37 | $0.00 |
DisclosureSEC source: 0001062993-21-004767 · form4.xml · derivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2031-05-16 F1 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on May 17, 2022 and vests as to 1/48 of the underlying shares monthly thereafter. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 14:51 UTC | Skye Bioscience, Inc. EMBI · Entity 8098 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001640334-20-002025 · form4.xml · derivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,736,541 Underlying: Common Stock · 4,000,000 shares Expires 2030-08-07 F1 · derivative.exercise_date: Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four years. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 20:25 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 95,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000899243-19-001926 · doc4.xml · derivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 17:06 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000899243-18-005337 · doc4.xml · derivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-02-22 F1 · derivative.exercise_date: 25% of this option vests on February 22, 2019, and the remainder vests in equal monthly installments thereafter over 36 months Read SEC document |
| July 11, 2017 Filed Jul 12, 2017 16:05 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | PurchaseCommon Stock | 10,000 | $3.39 | $33,900.00 |
DisclosureSEC source: 0000899243-17-018210 · doc4.xml · nonDerivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,443 Read SEC document |
| May 11, 2017 Filed May 11, 2017 18:59 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | PurchaseCommon Stock | 9,800 | $4.40 | $43,120.00 |
DisclosureSEC source: 0000899243-17-012901 · doc4.xml · nonDerivative · entry 2 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,443 F1 · balance_after: Includes 646 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan (the "Plan") on January 1, 2015, 699 shares acquired under the Plan on July 1, 2015 and 98 shares acquired under the Plan on January 1, 2016. Read SEC document |
| May 10, 2017 Filed May 11, 2017 18:59 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | PurchaseCommon Stock | 200 | $4.40 | $880.00 |
DisclosureSEC source: 0000899243-17-012901 · doc4.xml · nonDerivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,643 F1 · balance_after: Includes 646 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan (the "Plan") on January 1, 2015, 699 shares acquired under the Plan on July 1, 2015 and 98 shares acquired under the Plan on January 1, 2016. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 17:31 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 88,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0000899243-17-002287 · doc4.xml · derivative · entry 1 KIM DENNIS D · CIK 0001456750 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,000 Underlying: Common Stock · 88,000 shares Expires 2027-01-27 F1 · derivative.exercise_date: 25% of this option vests on January 27, 2018, and the remainder vests in equal monthly installments thereafter over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.